These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 11280720)

  • 1. The 104-123 amino acid sequence of the beta-domain of von Hippel-Lindau gene product is sufficient to inhibit renal tumor growth and invasion.
    Datta K; Sundberg C; Karumanchi SA; Mukhopadhyay D
    Cancer Res; 2001 Mar; 61(5):1768-75. PubMed ID: 11280720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transforming growth factor beta1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma.
    Ananth S; Knebelmann B; Grüning W; Dhanabal M; Walz G; Stillman IE; Sukhatme VP
    Cancer Res; 1999 May; 59(9):2210-6. PubMed ID: 10232610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells.
    Koochekpour S; Jeffers M; Wang PH; Gong C; Taylor GA; Roessler LM; Stearman R; Vasselli JR; Stetler-Stevenson WG; Kaelin WG; Linehan WM; Klausner RD; Gnarra JR; Vande Woude GF
    Mol Cell Biol; 1999 Sep; 19(9):5902-12. PubMed ID: 10454537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
    Kaelin WG
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity.
    Blankenship C; Naglich JG; Whaley JM; Seizinger B; Kley N
    Oncogene; 1999 Feb; 18(8):1529-35. PubMed ID: 10102622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids.
    Lieubeau-Teillet B; Rak J; Jothy S; Iliopoulos O; Kaelin W; Kerbel RS
    Cancer Res; 1998 Nov; 58(21):4957-62. PubMed ID: 9810005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of insulin-like growth factor-I-mediated cell signaling by the von Hippel-Lindau gene product in renal cancer.
    Datta K; Nambudripad R; Pal S; Zhou M; Cohen HT; Mukhopadhyay D
    J Biol Chem; 2000 Jul; 275(27):20700-6. PubMed ID: 10748176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.
    Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER
    Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients.
    Lubensky IA; Gnarra JR; Bertheau P; Walther MM; Linehan WM; Zhuang Z
    Am J Pathol; 1996 Dec; 149(6):2089-94. PubMed ID: 8952541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
    Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
    Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-kappaB-dependent antiapoptotic pathway.
    Qi H; Ohh M
    Cancer Res; 2003 Nov; 63(21):7076-80. PubMed ID: 14612498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatic von Hippel-Lindau disease gene mutation in clear-cell renal carcinomas associated with end-stage renal disease/acquired cystic disease of the kidney.
    Yoshida M; Yao M; Ishikawa I; Kishida T; Nagashima Y; Kondo K; Nakaigawa N; Hosaka M
    Genes Chromosomes Cancer; 2002 Dec; 35(4):359-64. PubMed ID: 12378530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones.
    Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T
    Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal cell carcinoma development in the rat independent of alterations at the VHL gene locus.
    Walker C; Ahn YT; Everitt J; Yuan X
    Mol Carcinog; 1996 Feb; 15(2):154-61. PubMed ID: 8599582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia.
    Gunningham SP; Currie MJ; Han C; Turner K; Scott PA; Robinson BA; Harris AL; Fox SB
    Cancer Res; 2001 Apr; 61(7):3206-11. PubMed ID: 11306510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Requirement for the von Hippel-Lindau tumor suppressor gene for functional epidermal growth factor receptor blockade by monoclonal antibody C225 in renal cell carcinoma.
    Perera AD; Kleymenova EV; Walker CL
    Clin Cancer Res; 2000 Apr; 6(4):1518-23. PubMed ID: 10778984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal.
    Pause A; Lee S; Lonergan KM; Klausner RD
    Proc Natl Acad Sci U S A; 1998 Feb; 95(3):993-8. PubMed ID: 9448273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation.
    Brauch H; Weirich G; Brieger J; Glavac D; Rödl H; Eichinger M; Feurer M; Weidt E; Puranakanitstha C; Neuhaus C; Pomer S; Brenner W; Schirmacher P; Störkel S; Rotter M; Masera A; Gugeler N; Decker HJ
    Cancer Res; 2000 Apr; 60(7):1942-8. PubMed ID: 10766184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.